Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ...

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Pedro C. Barata, MD, MSc, discusses a typical process for an oncologist to patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer.

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An expert emphasizes that treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) are highly ...